Our work suggests that testing for <i>COL7A1</i> genetic variants should be considered in patients with EBA, which either have a patient history hinting towards underlying dystrophic epidermolysis bullosa or pose therapeutic challenges. The gene discussed is COL7A1; the disease is acquired epidermolysis bullosa.